MCID: GND003
MIFTS: 40

Gonadal Disease

Categories: Endocrine diseases

Aliases & Classifications for Gonadal Disease

MalaCards integrated aliases for Gonadal Disease:

Name: Gonadal Disease 12 14
Gonadal Disorders 42 69
Gonadal Dysfunction 52

Classifications:



External Ids:

Disease Ontology 12 DOID:2277
MeSH 42 D006058
NCIt 47 C26786
UMLS 69 C0018050

Summaries for Gonadal Disease

Disease Ontology : 12 An endocrine system disease that is located in the gonads.

MalaCards based summary : Gonadal Disease, also known as gonadal disorders, is related to prolactin producing pituitary tumor and african histoplasmosis. An important gene associated with Gonadal Disease is POMC (Proopiomelanocortin), and among its related pathways/superpathways are Peptide ligand-binding receptors and GPCRs, Other. The drugs Ezetimibe and Methyltestosterone have been mentioned in the context of this disorder. Affiliated tissues include ovary, breast and bone, and related phenotypes are endocrine/exocrine gland and homeostasis/metabolism

Related Diseases for Gonadal Disease

Diseases related to Gonadal Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 108)
id Related Disease Score Top Affiliating Genes
1 prolactin producing pituitary tumor 10.9 IGF1 POMC
2 african histoplasmosis 10.9 GNRH1 POMC
3 lymphoma, gastric non hodgkins type 10.8 GH1 POMC
4 aortic valve atresia 10.8 GH1 POMC
5 lactic acidosis 10.8 GH1 GNRH1 POMC
6 benign peritoneal mesothelioma 10.7 GNRH1 NR5A1 POMC
7 lymphoepithelioma-like carcinoma 10.7 GNRH1 POMC
8 anterior spinal artery stroke 10.7 NR5A1 SRY
9 protein s deficiency 10.7 GH1 IGF1 POMC
10 hypothyroidism, congenital, nongoitrous 4 10.7 GH1 IGF1 POMC
11 ulcerative blepharitis 10.7 CRH IGF1 POMC
12 diencephalic neoplasm 10.7 GH1 GNRH1 POMC
13 febrile infection-related epilepsy syndrome 10.7 CRH IGF1 POMC
14 traumatic glaucoma 10.7 CRH IGF1 POMC
15 acute myocarditis 10.7 CRH GNRH1 POMC
16 spermatogenic failure, y-linked, 1 10.7 FSHR NR5A1 SRY
17 cardiovascular organ benign neoplasm 10.7 CRH IGF1 POMC
18 psychogenic movement 10.7 GH1 IGF1 POMC
19 cold-induced sweating syndrome 2 10.7 CRH GH1 POMC
20 molybdenum cofactor deficiency b 10.7 GH1 IGF1 POMC
21 vertebral artery occlusion 10.7 GNRH1 POMC
22 acute myeloid leukemia, susceptibility, gata2-related 10.7 CRH GH1 POMC
23 vestibular gland benign neoplasm 10.7 CRH IGF1 POMC
24 adrenal cortex disease 10.7 CRH GH1 POMC
25 lipase deficiency, combined 10.7 GH1 IGF1
26 progressive familial heart block, type ib 10.6 GNRH1 GNRHR
27 pituitary adenoma, acth-secreting 10.6 GH1 IGF1 POMC
28 vallecula cancer 10.6 CRH IGF1 POMC
29 autoimmune disease of central nervous system 10.6 AR CRH POMC
30 osteopathia striata with cranial sclerosis 10.6 AR SHBG
31 hypogonadism 10.6
32 inherited metabolic disorder 10.6 IGF1 POMC SHBG
33 hole retinal cyst 10.6 AR GNRH1
34 thymus mucoepidermoid carcinoma 10.6 AMH GNRH1 SRY
35 ovarian hyperstimulation syndrome 10.6 AMH FSHR GNRH1
36 ulceroglandular tularemia 10.6 AR SHBG
37 intermittent squint 10.6 CRH GH1 GNRH1 POMC
38 survival motor neuron spinal muscular atrophy 10.6 IGF1 POMC SHBG
39 alpha-methylacyl-coa racemase deficiency 10.6 GH1 GNRH1 IGF1 POMC
40 trabecular follicular adenocarcinoma 10.6 CRH NR0B1 POMC
41 bronchiectasis 10.6 CRH NR0B1 POMC
42 centrotemporal epilepsy 10.6 NR0B1 NR5A1 POMC
43 pelvic muscle wasting 10.5 GNRH1 IGF1 POMC SHBG
44 porokeratosis 10.5 FSHR GNRH1 IGF1 SHBG
45 thrombophilia 10.5 GH1 GNRH1 IGF1 POMC
46 uterine corpus adenocarcinofibroma 10.5 CRH GNRH1 POMC SHBG
47 renal pelvis carcinoma 10.5 CRH POMC
48 multiple synostoses syndrome 10.5 AMH NR5A1 SRY
49 idiopathic recurrent pericarditis 10.5 NR0B1 NR5A1 SRY
50 retroperitoneal sarcoma 10.5 AMH GNRH1 SHBG

Graphical network of the top 20 diseases related to Gonadal Disease:



Diseases related to Gonadal Disease

Symptoms & Phenotypes for Gonadal Disease

MGI Mouse Phenotypes related to Gonadal Disease:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.25 NR5A1 POMC PROKR2 AMH AR CRH
2 homeostasis/metabolism MP:0005376 10.21 GNRH1 GNRHR IGF1 KISS1 KISS1R NR0B1
3 growth/size/body region MP:0005378 10.18 KISS1 KISS1R NR5A1 POMC PROKR2 SHOX2
4 integument MP:0010771 10.02 AR CRH FSHR GNRH1 GNRHR IGF1
5 adipose tissue MP:0005375 9.93 AR CRH FSHR IGF1 KISS1 POMC
6 nervous system MP:0003631 9.9 AR CRH FSHR GNRH1 IGF1 KISS1
7 neoplasm MP:0002006 9.8 AMH AR FSHR GNRH1 IGF1 NR0B1
8 renal/urinary system MP:0005367 9.56 AR CRH GNRH1 GNRHR IGF1 KISS1
9 reproductive system MP:0005389 9.36 AMH AR FSHR GNRH1 GNRHR IGF1

Drugs & Therapeutics for Gonadal Disease

Drugs for Gonadal Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 718)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ezetimibe Approved Phase 4 163222-33-1 150311
2
Methyltestosterone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-18-4 6010
3
Testosterone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 58-22-0 6013
4
Cyproterone Acetate Approved, Investigational Phase 4,Phase 2,Phase 3,Early Phase 1 427-51-0
5
Estradiol Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-28-2 5757
6
Ethinyl Estradiol Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-63-6 5991
7
Leuprolide Approved, Investigational Phase 4,Phase 3,Phase 2,Early Phase 1 53714-56-0 3911 657181
8
Metformin Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 657-24-9 14219 4091
9
Ganirelix Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 123246-29-7, 124904-93-4 25081094
10
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
11
Drospirenone Approved Phase 4,Phase 3,Phase 2,Phase 1 67392-87-4 68873
12
Progesterone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 57-83-0 5994
13
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
14
Dihydrotachysterol Approved Phase 4,Phase 2,Phase 1 67-96-9 5281010 5311071
15
Letrozole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 112809-51-5 3902
16
Zinc Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 7440-66-6 32051 23994
17
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-23-7 5754 657311
18
Pioglitazone Approved, Investigational Phase 4,Early Phase 1 111025-46-8 4829
19
Epinephrine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 51-43-4 5816
20 Racepinephrine Approved Phase 4,Phase 2,Phase 3,Phase 1
21
Simvastatin Approved Phase 4 79902-63-9 54454
22
Benzocaine Approved Phase 4,Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
23
Everolimus Approved Phase 4,Phase 2,Phase 1 159351-69-6 6442177
24
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 1 22916-47-8 4189
25
Prednisone Approved, Vet_approved Phase 4,Phase 2,Phase 3 53-03-2 5865
26
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
27
Triamcinolone Approved, Vet_approved Phase 4,Phase 3 124-94-7 31307
28
Lenograstim Approved Phase 4,Phase 2,Phase 3,Phase 1 135968-09-1
29
Carboplatin Approved Phase 4,Phase 3,Phase 2,Phase 1 41575-94-4 10339178 498142 38904
30
Olaparib Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 763113-22-0 23725625
31
Liraglutide Approved Phase 4 204656-20-2 44147092
32
Dutasteride Approved, Investigational Phase 4,Phase 2,Phase 1 164656-23-9 152945 6918296
33
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
34
Menotropins Approved Phase 4,Phase 1,Phase 2 61489-71-2, 9002-68-0 5360545
35
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3 616-91-1 12035
36
Buserelin Approved Phase 4 57982-77-1
37
Nafarelin Approved Phase 4 76932-56-4 16129618 25077649
38
Aspirin Approved, Vet_approved Phase 4,Phase 2 50-78-2 2244
39
Rosiglitazone Approved, Investigational Phase 4 122320-73-4 77999
40
Hyaluronic acid Approved, Vet_approved Phase 4 9004-61-9 53477741 24759
41
Citalopram Approved Phase 4 59729-33-8 2771
42
Moxonidine Approved Phase 4 75438-57-2 4810
43
Alogliptin Approved Phase 4 850649-61-5 11450633
44
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
45
Etoricoxib Approved, Investigational Phase 4 202409-33-4 123619
46
Danazol Approved Phase 4 17230-88-5 28417
47
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2 141758-74-9 15991534
48
Iron Approved Phase 4 7439-89-6 23925
49
Anastrozole Approved, Investigational Phase 4,Phase 2,Phase 1 120511-73-1 2187
50
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2 104987-11-3 445643 439492

Interventional clinical trials:

(show top 50) (show all 2239)

id Name Status NCT ID Phase Drugs
1 A Study Evaluating the Effects of Lipid Lowering Treatment on Steroid Synthesis Unknown status NCT00433823 Phase 4 Atorvastatin, Ezetimibe
2 Assessment Of Gh-Igf-1 Axis In Children With Chronic Myelogenous Leukemia (CML) In Remission Unknown status NCT01901666 Phase 4 Growth Hormone
3 Testosterone for Peripheral Vascular Disease Unknown status NCT00504712 Phase 4 Testosterone;0.9% saline
4 Efficacy and Safety of Pulsatile Gonadotropin Releasing Hormone Pump Treatment in Patients With Idiopathic Hypogonadotropic Hypogonadism Unknown status NCT02310074 Phase 4 Pulsatile Gonadotropin Releasing Hormone;Human chorionic gonadotropin;Urinary Follicle-Stimulating Hormone
5 Myoinositol for the Treatment of Ovarian and Psychiatric Disorder in Polycystic Ovary Syndrome (PCOS) Patients Unknown status NCT01246310 Phase 4
6 Odense Androgen Study - The Effect of Testim and Training in Hypogonadal Men Unknown status NCT00700024 Phase 4 Testim;placebo
7 the Effect of Diane-35 Pretreatment on In-vitro Fertilization Outcome for Patients With Polycystic Ovary Syndrome Unknown status NCT01752270 Phase 4 Diane-35 pretreatment;Diane-35 pretreatment
8 Open-label, Follow-up Study of Oral Testosterone Undecanoate in Hypogonadal Men Unknown status NCT01699178 Phase 4 Oral testosterone undecanoate;Transdermal testosterone gel (AndroGel)
9 Comparative Validation of the Triptorelin Test for the Diagnosis of CPP in Girls Unknown status NCT01278290 Phase 4 Triptorelin acetate and Gonadorelin acetate;Gonadorelin acetate and Triptorelin acetate
10 Analysis of Genetic and Environmental Parameters Influencing Growth Rate of Precocious Puberty Children Unknown status NCT00438217 Phase 4 Triptorelin (GnRH agonists);Leuprolide (GnRH agonists)
11 Comparison of Assisted Reproductive Technology (ART) Outcomes Between Two Protocols of Induction of Ovulation in Patients With Hypogonadotropic Hypogonadism Unknown status NCT02140515 Phase 4 Lutropin alfa;Follitropin alfa and Lutropin alfa
12 Effect of Androgel on Type 2 Diabetic Males With Hypogonadism Unknown status NCT00350701 Phase 4 androgel;androgel 10g;placebo
13 Effect of Testosterone on Endothelial Function and Microcirculation in Type 2 Diabetic Patients With Hypogonadism Unknown status NCT01084369 Phase 4 Testosterone
14 Endometrial Scratching During Laproscopic Ovarian Drilling in Subfertile PCOS Women Unknown status NCT02140398 Phase 4
15 Strategies for Ovulation Induction in Anovulatory Infertile Patients With PCOS Unknown status NCT00461643 Phase 4 Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins
16 Therapeutic Monitoring of Metformin in Women With Polycystic Ovary Syndrome Unknown status NCT01366391 Phase 4 Metformin
17 Comparison Between GnRH Agonist and GnRH Antagonist Protocols of Ovarian Stimulation in PCOS Patients Unknown status NCT00417144 Phase 4 Arvekap 0.1mg (Triptorelin, Ipsen, France);Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
18 Surgical Ovarian Drilling Versus Hormonal Treatment for Infertility Associated to PolyCystic Ovaries Syndrome (PCOS) Unknown status NCT00378729 Phase 4 Metformin and FSHr
19 The Effect of Weight Loss on Anti-Müllerian Hormone Levels in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT01475019 Phase 4 Orlistat;Sibutramine
20 Metformin and Gestational Diabetes in High-risk Patients: a RCTs Unknown status NCT00883259 Phase 4 Metformin
21 The Impact on Ovarian Reserve After Single-port, Two-port, or Four-port Access Laparoscopic Ovarian Cyst Enucleation Unknown status NCT01631253 Phase 4
22 Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
23 Growth Response in Girls With Turner Syndrome Completed NCT01734486 Phase 4 somatropin;somatropin
24 Safety of Somatropin and Induction of Puberty With 17-beta-oestradiol in Girls With Turner Syndrome Completed NCT01518062 Phase 4 somatropin;somatropin;somatropin;oestrogen
25 Raloxifene and Rimostil for Perimenopause-Related Depression Completed NCT00030147 Phase 4 Raloxifene;Rimostil;Transdermal Estradiol;Placebo skin patch and placebo tablets
26 LIPT - Liraglutide in Polycystic Ovary Syndrome Completed NCT02073929 Phase 4 Liraglutide;placebo
27 Effects of Testosterone on Myocardial Repolarization Completed NCT03126656 Phase 4 Testosterone Undecanoate
28 Norditropin NordiFlex® Device Compared to the Device Previously Used by Patients or Parents Completed NCT01245374 Phase 4
29 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism Completed NCT00837616 Phase 4 17 B estradiol orally;17 B estradiol
30 Testosterone Therapy of Men With Type 2 Diabetes Mellitus (T2DM) Completed NCT01560546 Phase 4 Testosterone;Placebo
31 Testosterone Replacement in Older Men and Atherosclerosis Progression Completed NCT00287586 Phase 4 Testosterone Gel (Androgel);Placebo
32 The Effects of Vitamin D on Transforming Growth Factor-beta1 in Polycystic Ovary Syndrome Completed NCT02460380 Phase 4 Vitamin D3
33 Testosterone Replacement in Men With Diabetes and Obesity Completed NCT01127659 Phase 4 testosterone;placebo
34 Tumor Gene Expression in Women With Ovarian Cancer Completed NCT00817479 Phase 4 Dexamethasone;Placebo
35 Body Composition, Glucose Metabolism, Insulin Resistance and Gene Expression in Muscle Cells in Healthy Overweight Women Completed NCT00145392 Phase 4
36 Efficacy of Fenugreek Seed and Lespedeza Cuneata in TDS Completed NCT03057899 Phase 4 TFG capsules (200 mg /capsule);Placebo oral capsule
37 Study of Comprehensive Diagnosis and Treatment for Children Precocious Puberty Completed NCT02920515 Phase 4 Triptorlin or Leuprorelin;Zhibo dihuang pills;Dabu ying pills
38 The Effect of Testosteron Replacement Treatment on the Fibroblast Growth Factor-23, Asymmetric Dimethylarginine and Vitamin D Levels in the Congenital Hypogonadotropic Hypogonadism Completed NCT02111473 Phase 4 Testosterone
39 The Effect of Testosterone Topical Solution (LY900011) in Hypogonadal Men With Suboptimal Response to a Topical Testosterone Gel Completed NCT01893281 Phase 4 Topical Testosterone Solution
40 The Clinical Trial to Evaluate the Efficacy and Safety of Luphere Depot Inj. 3.75mg(Leuprolide Acetate 3.75mg) in Patients With Precocious Puberty Completed NCT01634321 Phase 4 Luphere depot 3.75mg(Leuprolide acetate 3.75mg)
41 Effects of Medications in Patients With Hypogonadism Completed NCT01601327 Phase 4 Testosterone enanthate (Sustanon 250 mg);Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU);Testosteron gel (Testojel 50 mg)
42 The Effect of Testosterone Replacement on the High Density Lipoprotein Cholesterol Subgroups Completed NCT01454011 Phase 4 Testosteron 250mg injection;Testosterone 50mg transdermal application
43 ESPRIT Study in Hypogonadal Men Completed NCT01143818 Phase 4 AndroGel (testosterone gel) 1%
44 Testosterone Replacement Therapy Decreases Plasma Paraoxonase 1 Enzyme Activity In Male Patients With Hypogonadism Completed NCT01107067 Phase 4 Sustanon
45 Efficacy Study for Use of Dutasteride (Avodart) With Testosterone Replacement Completed NCT00752869 Phase 4 dutasteride;placebo
46 Aripiprazole and Prolactin Study Completed NCT01085383 Phase 4 Aripiprazole
47 The Role of Estrogen in Luteinizing Hormone Surge and Ovulation Completed NCT01999569 Phase 4 Letrozole
48 Clinical Evaluation of Furocyst in Patients With Poly Cystic Ovary Syndrome Completed NCT02789488 Phase 4
49 Metformin and Lifestyle Intervention in Women With Polycystic Ovary Syndrome Completed NCT00679679 Phase 4 Metformin;Placebo
50 Metformin and Folate Supplementation in Polycystic Ovary Syndrome (PCOS) Patients Completed NCT00953355 Phase 4 Folate plus metformin;Placebo plus metformin

Search NIH Clinical Center for Gonadal Disease

Cochrane evidence based reviews: gonadal disorders

Genetic Tests for Gonadal Disease

Anatomical Context for Gonadal Disease

MalaCards organs/tissues related to Gonadal Disease:

39
Ovary, Breast, Bone, Testes, Lung, Liver, Brain

Publications for Gonadal Disease

Variations for Gonadal Disease

Expression for Gonadal Disease

Search GEO for disease gene expression data for Gonadal Disease.

GO Terms for Gonadal Disease

Cellular components related to Gonadal Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 AMH ANOS1 CRH GH1 GNRH1 IGF1
2 extracellular space GO:0005615 9.23 AMH ANOS1 CRH GH1 GNRH1 IGF1

Biological processes related to Gonadal Disease according to GeneCards Suite gene sharing:

(show all 19)
id Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.83 AMH AR GNRH1 NR5A1 POMC
2 neuropeptide signaling pathway GO:0007218 9.76 KISS1R POMC PROKR2
3 positive regulation of MAPK cascade GO:0043410 9.74 AR IGF1 KISS1
4 male gonad development GO:0008584 9.71 AR FSHR NR0B1 NR5A1
5 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.7 FSHR GH1 IGF1
6 steroid hormone mediated signaling pathway GO:0043401 9.65 AR NR0B1 NR5A1
7 intracellular receptor signaling pathway GO:0030522 9.63 AR NR0B1 NR5A1
8 hypothalamus development GO:0021854 9.58 CRH NR0B1
9 regulation of systemic arterial blood pressure GO:0003073 9.56 AR FSHR
10 Leydig cell differentiation GO:0033327 9.55 AR NR0B1
11 positive regulation of intracellular estrogen receptor signaling pathway GO:0033148 9.54 AR FSHR
12 sex differentiation GO:0007548 9.54 AMH AR SRY
13 positive regulation of male gonad development GO:2000020 9.51 NR5A1 SRY
14 adrenal gland development GO:0030325 9.5 CRH NR0B1 NR5A1
15 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.43 AR GH1 IGF1
16 gonad development GO:0008406 9.33 AMH FSHR NR0B1
17 male sex determination GO:0030238 9.13 GNRH1 NR0B1 SRY
18 sex determination GO:0007530 8.8 AMH NR0B1 NR5A1
19 signal transduction GO:0007165 10.15 AR CRH FSHR GNRH1 GNRHR IGF1

Molecular functions related to Gonadal Disease according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 sequence-specific DNA binding GO:0043565 9.77 AR NR0B1 NR5A1 SHOX SHOX2
2 steroid hormone receptor activity GO:0003707 9.5 AR NR0B1 NR5A1
3 G-protein coupled peptide receptor activity GO:0008528 9.4 FSHR KISS1R
4 RNA polymerase II transcription factor activity, ligand-activated sequence-specific DNA binding GO:0004879 9.33 AR NR0B1 NR5A1
5 protein-hormone receptor activity GO:0016500 9.26 FSHR GNRHR
6 hormone activity GO:0005179 9.1 AMH CRH GH1 GNRH1 IGF1 POMC
7 androgen binding GO:0005497 8.96 AR SHBG

Sources for Gonadal Disease

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....